DIMORPHOLAMINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H38N4O4
Molecular Weight	398.5401
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCN(CCN(CCCC)C(=O)N1CCOCC1)C(=O)N2CCOCC2

InChI

InChIKey=HZTMGWSBSDLALI-UHFFFAOYSA-N

InChI=1S/C20H38N4O4/c1-3-5-7-21(19(25)23-11-15-27-16-12-23)9-10-22(8-6-4-2)20(26)24-13-17-28-18-14-24/h3-18H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C20H38N4O4
Molecular Weight	398.5401
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://nippon.zaidan.info/seikabutsu/1996/00388/contents/061.htm
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/43915 and https://www.drugs.com/international/dimorpholamine.html

Dimorpholamine is reported as an ingredient of Theraptique in Japan. Dimorpholamine stimulates the respiratory and circulatory centers to increase the respiratory volume and blood pressure. It is indicated for the respiratory and circulatory insufficiency due to shock, hypnotic intoxication. drowning, pneumonia, and high fever.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
skeletal muscle contraction 3 Target ID: GO:0003009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/43915	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Respiratory and circulatory insufficiency 1 Sources: https://www.drugs.com/international/dimorpholamine.html	Primary		Approved 8429	Theraptique Approved Use Indications: Respiratory and circulatory insufficiency due to shock, hypnotic intoxication. drowning, pneumonia, and high fever.

PubMed

Title	Date	PubMed
Measurement of respiratory function using whole-body plethysmography in unanesthetized and unrestrained nonhuman primates.	2010 Dec	21139336

Patents

Sample Use Guides

In Vivo Use Guide

30-60 mg (1-2 ampoules) via the intramuscular route. If necessary, the same dose may be given repeatedly unless the daily dose exceeds 200 mg (6.5 ampoules).

Route of Administration: Intramuscular

In Vitro Use Guide

Low concentrations (about 2 x 10(-5) g/ml) of dimorpholamine potentiate the twitch contraction of frog sartorius muscle. In relatively high concentrations of 10(-4)--10(-3) g/ml, however, the potentiation was followed by depression.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:21:59 GMT 2023` Edited by `admin` on `Fri Dec 15 16:21:59 GMT 2023`
Record UNII	8YL4JT0L91
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIMORPHOLAMINE

Common Name

English

Dimorpholamine [WHO-DD]

Common Name

English

DIMORPHOLAMINE [JAN]

Common Name

English

N,N'-1,2-ETHANEDIYLBIS (N-BUTYL-4-MORPHOLINECARBOXAMIDE)

Systematic Name

English

DIMORPHOLAMINE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47795